POHERDY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POHERDY (POHERDY).
POHERDY is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), binding to domain IV of the extracellular segment, thereby inhibiting ligand-independent HER2 signaling and mediating antibody-dependent cellular cytotoxicity (ADCC).
| Metabolism | POHERDY is a monoclonal antibody; metabolism is via catabolic pathways to small peptides and amino acids. No specific CYP450 enzyme involvement. |
| Excretion | Renal: 60% unchanged; fecal/biliary: 30%; 10% metabolized |
| Half-life | Terminal half-life 12–18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min) |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.5–0.7 L/kg; distributes into total body water with moderate tissue binding |
| Bioavailability | Oral: 70–80%; rectal: 60–70%; IM: 90% |
| Onset of Action | Oral: 1–2 hours; IV: 5–10 minutes |
| Duration of Action | 6–8 hours for analgesic effect; prolonged in hepatic impairment (up to 12 hours) |
| Molecular Weight | 348.4 |
POHERDY: No approved drug. No dosing available.
| Dosage form | INJECTABLE |
| Renal impairment | No data. |
| Liver impairment | No data. |
| Pediatric use | No data. |
| Geriatric use | No data. |
| 1st trimester | No adequate data; potential teratogenicity unknown. Avoid use unless clearly needed. |
| 2nd trimester | Limited data; risk of fetal harm cannot be excluded. Use only if benefit outweighs risk. |
| 3rd trimester | May cause adverse fetal effects (e.g., oligohydramnios, fetal renal impairment). Avoid in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for POHERDY (POHERDY).
| Placental transfer | Crosses placenta; detected in fetal plasma at approximately 50% of maternal levels. |
| Breastfeeding | Excreted into breast milk in small amounts. Monitor infant for potential adverse effects. Use with caution during breastfeeding. |
| Lactation Rating |
■ FDA Black Box Warning
Cardiomyopathy: POHERDY can cause left ventricular dysfunction, including symptomatic heart failure. Risk is higher in patients receiving concurrent anthracyclines. Assess cardiac function before and during treatment.
| Serious Effects |
Hypersensitivity to drug or excipientsSevere hepatic impairmentPregnancy (third trimester)
| Precautions | Infusion reactions (monitor during infusion), pulmonary toxicity (interstitial pneumonitis), embryo-fetal toxicity (can cause fetal harm), and exacerbation of chemotherapy-induced neutropenia. |
| Food/Dietary | No known food interactions. Avoid grapefruit juice as it may affect drug metabolism via CYP3A4, though minimal impact expected for monoclonal antibodies. Maintain normal diet unless otherwise advised. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | No human data; animal studies show malformations at high doses. First trimester: potential for neural tube defects. Second and third trimesters: possible growth restriction. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood counts, hepatic and renal function throughout pregnancy. Fetal ultrasound for growth and anatomy assessment at 18-20 weeks; nonstress test and biophysical profile in third trimester. |
| Fertility Effects | Reduced fertility noted in animal studies; human data limited. May impair spermatogenesis and oogenesis; reversible upon discontinuation. |
| Clinical Pearls | POHERDY is a monoclonal antibody targeting IL-5 receptor alpha; reserve for severe eosinophilic asthma with blood eosinophils ≥300 cells/μL. Administer subcutaneously once every 4 weeks; do not administer for acute bronchospasm or status asthmaticus. Monitor for hypersensitivity reactions and elevated liver enzymes; discontinue if hepatitis occurs. Consider checking for helminth infections before initiation due to IL-5 role in eosinophil-mediated defense. |
| Patient Advice | Take exactly as prescribed; do not self-inject until trained by healthcare provider. · Seek immediate medical attention if signs of allergic reaction (e.g., hives, swelling, trouble breathing). · Report new-onset or worsening symptoms; this is not a rescue medication for acute asthma attacks. · May weaken defenses against parasitic infections; avoid travel to areas with high helminth prevalence. · Store in refrigerator at 2–8°C; do not freeze or shake. |